Bicycle Therapeutics to Attend June 2024 Investor Conferences

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company listed on NASDAQ under the ticker BCYC, has made an announcement concerning its participation in several upcoming investor conferences in June 2024. Bicycle Therapeutics, which is at the forefront of developing a unique class of therapeutics based on its proprietary bicyclic peptide technology, will be represented by its management team at the following events:

- The Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, with a fireside chat scheduled at 8:30 a.m. ET.
- The Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, with a fireside chat at 1:20 p.m. ET.
- The TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit on Monday, June 17, 2024, featuring a fireside chat at 3:00 p.m. ET.

These discussions will be broadcast live on the company's website in the Investor section, and recordings will be available after the events.

Bicycle Therapeutics specializes in creating a novel class of medicines known as Bicycle® molecules. These are entirely synthetic, short peptides constrained by small molecule scaffolds, forming two loops that stabilize their structural shape. This design enables high-affinity and selective binding to targets, making Bicycle molecules promising candidates for drug development.

The company is conducting clinical trials on several of its innovative candidates:
- Zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) that targets Nectin-4, a well-established tumor antigen.
- BT5528, another BTC molecule, targets EphA2, a protein that has previously been difficult to address in cancer treatments.
- BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®), which targets Nectin-4 and stimulates CD137, a costimulatory molecule in the immune system.

Apart from these, Bicycle Therapeutics is working on Bicycle® Radio Conjugates (BRC™) for use in radiopharmaceuticals. The company is also exploring broader applications of its Bicycle® technology, extending beyond oncology through various partnerships.

Headquartered in Cambridge, UK, Bicycle Therapeutics has significant operational functions and leadership based in Cambridge, Massachusetts. This strategic bi-coastal presence supports its innovative research and development activities.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!